Personer som var seronegative for anti- HPV 6, 11, 16, 18 i cLIA ved forsøgets afslutning stadig var beskyttet imod klinisk sygdom.
Subjects who were seronegative for anti-HPV 6, 11, 16, 18 in the cLIA at end of study were still protected against clinical disease.